Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet

Diabetes, Obesity and Metabolism

Volumn 11, Issue 9, 2009, Pages 865-873

  Raskin, Philip ^a,d   Lewin, A ^b   Reinhardt, R ^c   Lyness, W ^c   Adler, Jay ^d   Ahmed, Azazuddin ^d   Ahmed, Khursheed ^d   Anderson, Donald ^d   Argoud, Georges ^d   Arif, Ahmed ^d   Ashinsky, Douglas ^d   Awad, Ahmed ^d   Azorr, Michael ^d   Bailey, Dwight ^d   Baker, Claire ^d   Bartilucci, Darlene ^d   Bays, Harold ^d   Bedel, Gary ^d   Bellinger, Raye ^d   Bode, Bruce ^d   Breakey, Robert ^d   Brusco, Osvaldo ^d   Cade, Jerry ^d   Call, Robert ^d   Chandler, John ^d   Chaykin, Louis ^d   Cheung, Deanna ^d   Crabtree, Yvette ^d   Crockett, Samuel ^d   Cunnar, James ^d   Dow, H John ^d   Downey, Jackson ^d   Drehobl, Margaret ^d   Dunn, Leonard ^d   Erman, Milton ^d   Fitz Patrick, David ^d   Farmer, Frank H ^d   Ferrera, David R ^d   Fraser, Neil ^d   Fusco, Frank ^d   Garber, Alan ^d   Gill, Santosh ^d   Gilman, Ronald ^d   Gilliam, John ^d   Gollapudi, Gopalakris ^d   Hassman, David ^d   Hutchins, Robert ^d   Jain, Rajeev ^d   Kairi, Rashid ^d   Kaye, William ^d   Kawley, Adam F ^d   Kayota, Stephen ^d   Kerzner, Boris ^d   Khronusova, Yekateri ^d   Klonoff, David ^d   Kumar, Mariananda ^d   Lala, Vinod ^d   Landgarten, Steven ^d   Lane, Wendy ^d   Lang, John ^d   Lang, Robert ^d   Leichter, Steven ^d   Lewin, Andrew ^d   Lipetz, Robert ^d   Littlejohn, Thomas ^d   Lynn, Lon ^d   Madsen, Daniel ^d   Maggiacomo, Frank ^d   Maletz, Louis ^d   Malkin, Steven ^d   Marple, Richard ^d   McNeil, Robert ^d   Messina, Nicholas ^d   Meyers, Peter ^d   Mills, Richard ^d   Morawski, Emily ^d   Mullen, Julie ^d   O'Barr, Thomas ^d   Pearlstein, Robert ^d   Perlman, Neil ^d   Peterson, Gregory ^d   Pollock, Jeffrey ^d   Popeil, Larry ^d   Pragalos, Antoinette ^d   Race, James ^d   Radin, David ^d   Raval, Pramod ^d   Ratner, Robert ^d   Reynolds, Albert ^d   Riveland, Brian ^d   Colon, Luis Rivera ^d   Schwartz, Sherwyn ^d   Shusman, Robert ^d   Silkiner, David ^d   Smith, William ^d   Snell, Philip ^d   Soler, Norman ^d   Snyder, Brian ^d   Stringam, Stanley ^d   Sugimoto, Danny ^d   Tamayo, Raul ^d   Tanenberg, Robert ^d   Touger, Scott M ^d   Townsend, Richard ^d   Turner, Jeannine ^d   Weerasinghe, Mervyr ^d   Wynne, Alan ^d   Yates, Scott ^d   Yeoman, Gary ^d   more..

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NATIONAL RESEARCH INSTITUTE   (United States)

^c NOVO NORDISK INC   (United States)

^d NONE

Author keywords

Antidiabetic drugs; Clinical trials; Diabetes; Glycaemic control; Repaglinide

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIPID; METFORMIN; METFORMIN PLUS REPAGLINIDE; METFORMIN PLUS ROSIGLITAZONE; REPAGLINIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIABETIC NEUROPATHY; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART VENTRICLE FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEPHROLITHIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRESYNCOPE; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; TABLET FORMULATION; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CARBAMATES; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METFORMIN; MIDDLE AGED; PATIENT SATISFACTION; PIPERIDINES; TABLETS; THIAZOLIDINEDIONES; YOUNG ADULT;

EID: 69249213686     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01062.x     Document Type: Article

References (15)

1. Moses R. Repaglinide in combination therapy with metformin in type 2 diabetes. Exp Clin Endocrinol Diabetes 1999; 107 (Suppl. 4): S136-S139.
2. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007; 120: 713-719.
3. Moses R, Slobodniuk R, Boyages S et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-124.
4. Raskin P, Klaff L, McGill J et al. Efficacy and safety of combination therapy: Repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003; 26: 2063-2068.
5. Reboussin DM, Goff DC Jr, Lipkin EW et al. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. Diabet Med 2004; 21: 1082-1089.
6. Rudovich NN, Leyck Dieken MG, Rochlitz H, Pfeiffer AF. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2004; 112: 395-400.
7. Shapiro MS, Abrams Z, Lieberman N. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. Isr Med Assoc J 2005; 7: 75-77.
8. Soegondo S, Subekti I, Luthariana L. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients. Acta Med Indones 2004; 36: 142-147.
9. Prandin® (repaglinide) Tablets Prescribing Information. Available from URL: http://www.prandin.com/docs/prandin_insert.pdf. Accessed 3 March 2009.
10. Raskin R, Lewin A, Reinhardt R, Lyness W. Twice-Daily and Three-Times daily dosing of a Repaglinide/Metformin fixed-dose combination tablet provide similar glycemic control. Diabetes, Obesity and Metabolism 2009; in press; DOI 10.1111/j.1463-1326.2009.01069.x
11. Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. FDA Guidance for Industry, 2008. Available from URL: http://www.fda.gov/cder/guidance/7630dft.htm. Accessed 3 March 2009.
12. International Product Safety, Novo Nordisk A/S, Bagsvaerd, Denmark. Data on file 2008.
13. Vamecq J, Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999; 354: 141-148.
14. AVANDIA® (rosiglitazone maleate) Tablets Prescribing Information. Available from URL: http://us.gsk.com/products/assets/us_avandia.pdf. Accessed 3 March 2009.
15. AVANDAMET® (rosiglitazone maleate and metformin hydrochloride) Tablets Prescribing Information. Available from URL: http://us.gsk.com/ products/assets/us_avandia.pdf. Accessed 3 March 2009.